• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial
CONCLUSION: The addition of colchicine to standard medical therapy in ACS patients significantly reduces MACE occurrence and improves survival rate over the time.PMID:34876021 | DOI:10.1186/s12872-021-02393-9
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mehdi Akrami Peyman Izadpanah Mehdi Bazrafshan Unes Hatamipour Navid Nouraein Hamed Bazrafshan Drissi Alireza Manafi Source Type: research

Clinical Outcomes of Acute Myocardial Infarction Hospitalizations with Systemic Lupus Erythematosus: An Analysis of Nationwide Readmissions Database
CONCLUSION: Patients with AMI and SLE had higher inpatient mortality during the index hospitalization and higher 30-day hospital readmissions compared to AMI patients without SLE. There were no significant differences in most of the other major inpatient outcomes between the two cohorts.PMID:34936910 | DOI:10.1016/j.cpcardiol.2021.101086
Source: Atherosclerosis - December 22, 2021 Category: Cardiology Authors: Shazib Sagheer Pallav Deka Dola Pathak Umair Khan Syeda Humna Zaidi Anum Akhlaq James Blankenship Ann Annis Source Type: research

Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention
CONCLUSION: The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.PMID:35537720 | DOI:10.15537/smj.2022.43.5.20220018
Source: Atherosclerosis - May 10, 2022 Category: Cardiology Authors: Seyed Mohammad H Adel Fateme Jorfi Hoda Mombeini Homeira Rashidi Saad Fazeli Source Type: research

A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
In conclusion, these results suggest cilostazol may have beneficial effects in patients with CAD or at a high risk of CV disease.PMID:35743723 | DOI:10.3390/jpm12060938
Source: Atherosclerosis - June 24, 2022 Category: Cardiology Authors: Jia-Ling Lin Wei-Kung Tseng Po-Tseng Lee Cheng-Han Lee Shih-Ya Tseng Po-Wei Chen Hsien-Yuan Chang Ting-Hsing Chao Source Type: research